We have attached herewith announcement as per Reg. 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.

October 29, 2026 To, To, Listing Department, The National Stock Exchange of BSE Limited India Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Subject: Intimation of receipt of 'In-Principle' Approval under Regulation 30 of SEBI (LODR) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has received 'In-Principle' approval from the NSE and BSE for the proposed issuance of 8,05,35,651 equity shares of Rs. 2/- each, pursuant to the proposed share swap, on a preferential basis, in terms of Chapter V of the SEBI (ICDR) Regulations, 2018 and in terms of the following letters received from each of them: 01. National Stock Exchange of India Limited, vide letter no. NSE/LIST/56913 dated 28/10/2026; and 02. BSE Limited, vide letter no. LOD/PREF/DA/FIP/1029/2026-27 dated 28/10/2026 Request you to kindly take the same on record. Thanking You. For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in